NCT06062771已完成不适用
A Prospective, Single-center, Within Patient Randomized, Noninferiority, Controlled, Single-masked Clinical Investigation to Evaluate Efficacy and Safety of the Use of Ophthalmic Viscosurgical Devices (OVD) FIDIAL PLUS vs IAL®-F During Cataract Surgery
Fidia Farmaceutici s.p.a.2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2022年7月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Change of corneal endothelium cell density after phacoemulsification cataract surgery with use of two different OVD (Ophthalmic Viscosurgical Devices)
研究概览
简要总结
This is a Prospective, single-center, randomized, controlled, paired-eye, single-masked clinical investigation to compare the efficacy and safety of FIDIAL PLUS (bacterial derived 1.8% sodium hyaluronate OVD) and IAL®-F (comparable animal derived 1.8% sodium hyaluronate OVD) while used during phacoemulsification cataract surgery.
详细描述
Viscoelastics, also referred to as OVDs (ophthalmic viscosurgical devices), are viscous substances that are routinely used in cataract surgery. The most basic benefit of OVD use in ophthalmic surgery is maintaining the anterior chamber during surgical maneuvers. One of the main aspects in OVD use remains the protection of intraocular structures and in particular of corneal endothelium cells (CECs) during cataract surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject able to comprehend the full nature and the purpose of the study;
- •Subjects able to cooperate with the Investigator and to comply with the requirements of the entire study;
- •Subject provided written informed consent to participate in the study obtained according to Good Clinical Practice (GCP);
- •Females of childbearing potential (i.e., not permanently sterilised - post hysterectomy or tubal ligation status - or not postmenopausal) must have a negative urine pregnancy test result at Screening and surgery days and must use an appropriate method of contraception for at least 30 days before inclusion in the study and during the whole study period, according to the definition in ICH M3 Guideline.
- •The following criteria apply to both eyes:
- •Nuclear cataract with visual acuity between 20/200 (logmar 1.0) and 20/32 (logmar 0.2);
- •Intraocular pressure (IOP) between 14 and 21 mmHg (Goldmann tonometer);
- •Previous refraction between -5 and +3 diopters in spherical equivalent;
- •Corneas perfectly transparent without leukoma or other corneal pathology.
排除标准
- •Any acute, chronic or uncontrolled disease as severe heart failure, recent cardiovascular event, respiratory failure, severe hepatic or renal disease, poorly controlled diabetes mellitus, active severe autoimmune disease, active malignancy etc. that in the opinion of the Investigator, would increase the risk of operation or affect the outcome of the study;
- •Epilepsy and any other condition that would prevent cooperation during surgery, including head tremor, deafness, neck or back problems, restless legs syndrome, claustrophobia etc.;
- •Have a history of allergic/hypersensitivity reaction to sodium hyaluronate (NaHA);
- •Participation in another clinical trial within the past 30 days;
- •The following criteria apply both eyes:
- •Corneal endothelium cell density less than 1800 cells/mm square;
- •Pseudoexfoliation syndrome (PEX) or suspected zonular compromise of any origin;
- •Corneal angle narrow or/and glaucoma;
- •Anterior segment pathology likely to increase the risk of an adverse outcome for phacoemulsification cataract surgery (e.g., pseudoexfoliation syndrome, synechiae, iris atrophy, inadequate dilation, shallow anterior chamber, traumatic cataract, lens subluxation etc.);
- •Any corneal irregularity or leukoma (as assessed by slit lamp and specular microscope pachymetry);
- •Complicated cataracts;
- •Subjects requiring implantation of toric lenses;
- •Proliferative retinopathy, macular degeneration or oedema of any origin. Other ocular pathology that may compromise vision despite successful cataract surgery;
- •Signs of ocular or systemic infection and/or inflammation;
- •Previous intraocular surgery, refractive surgery or severe ocular trauma.
结局指标
主要结局
Change of corneal endothelium cell density after phacoemulsification cataract surgery with use of two different OVD (Ophthalmic Viscosurgical Devices)
时间窗: 28 days per eye
This outcome will be calculated as percentage of corneal endothelial cells loss at day 28 (T3/T6) when compared with baseline (T0). This will be assessed as a paired t-test comparing the mean percentage change of FIDIAL PLUS against the mean percentage change from baseline of IAL®-F at Day 28. Corneal endothelial cell density will be measured by non-contact specular microscopy.
次要结局
- Incidence of ocular Treatment Emergent Adverse Events (TEAEs)(up to 28 days)
- Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6) of corneal edema(Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6))
- Incidence of a significant (≥30 mmHg) rise in IOP (Intraocular pressure) during study duration(28 days per eye)
- Central corneal Thickness changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6)(Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6))
- Change at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6) of corneal endothelial morphology(Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6))
- Incidence of serious ocular Treatment Emergent Adverse Events(up to 28 days)
- Change at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6) of Intraocular pressure (IOP)(Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6))
- Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6) of BCVA (Best corrected distance visual acuity)(Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6))
- Incidence and grade of anterior chamber inflammation (cells and flare measurement)(Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6))
- Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6) of UDVA (Uncorrected distance visual acuity)(Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6))
研究者
研究点 (2)
Loading locations...
相似试验
终止
不适用
Dehydrated Human Amnion/Chorion Membrane Micrografts(dHACM) Injectable in the Treatment of Recalcitrant Plantar FasciitisPlantar FasciitisNCT01996111MiMedx Group, Inc.14
尚未招募
不适用
A Clinical Study to Evaluate the Efficacy and Satisfaction of the Skinceuticals Skin Care Product (CE FERULIC) for Skin Repair Post Fraxel Laser TreatmentPhoto-damagingNCT06026085DeYi Aesthetic Medical Clinic50
尚未招募
不适用
A Clinical Study to Evaluate the Efficacy and Satisfaction of the Skinceuticals Skin Care Product (CE) for Skin Repair Post Fraxel Laser TreatmentPhoto-damagingNCT05813483DeYi Aesthetic Medical Clinic50
撤回
不适用
AMIC vs. MFx in the AnkleOsteochondral Lesion of TalusChondral DefectMicrofractureNCT05741983Geistlich Pharma AG
已完成
不适用
RHA® 4 NLF CannulaWrinkleNasolabial FoldAgingNCT04754646Teoxane SA50